Director at Trevi Therapeutics (NASDAQ: TRVI) awarded 35,000 stock options

Rhea-AI Filing Summary

Trevi Therapeutics director Anne Vanlent received a grant of stock options covering 35,000 shares of common stock. The nonstatutory options have an exercise price of $13.45 per share and expire on June 2, 2036. All 35,000 underlying shares are scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual meeting of stockholders, as long as she continues serving as a director, employee or consultant. Following this award, her reported derivative holdings from this grant total 35,000 options, reflecting a routine compensation-related acquisition rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider VANLENT ANNE

Role null

Type	Security	Shares	Price	Value
Grant/Award	Nonstatutory Stock Option (right to buy)	35,000	$0.00	--

Holdings After Transaction: Nonstatutory Stock Option (right to buy) — 35,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 35,000 shares Exercise price: $13.45 per share Expiration date: June 2, 2036 +2 more

5 metrics

Option grant size 35,000 shares Nonstatutory stock option covering common stock

Exercise price $13.45 per share Exercise price of nonstatutory stock option

Expiration date June 2, 2036 Option expiration for 35,000-share grant

Shares underlying options 35,000 shares Underlying common stock for granted options

Shares following transaction 35,000 derivative shares Total options held from this grant after award

Key Terms

Nonstatutory Stock Option, exercise price, expiration date, annual meeting of stockholders, +1 more

5 terms

Nonstatutory Stock Option financial

"Nonstatutory Stock Option (right to buy)"

A nonstatutory stock option (also called a non-qualified stock option) is an employee or contractor right to buy company shares at a set price that does not qualify for special tax treatment. When exercised, the difference between the market price and the set price is treated as ordinary income for the recipient and usually triggers payroll tax and withholding. For investors, these options matter because they create potential share dilution, affect reported compensation costs, and influence the timing of when new shares enter the market—similar to a coupon that lets someone buy stock at a discount but results in an immediate tax bill.

exercise price financial

"conversion_or_exercise_price": "13.4500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2036-06-02T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"the date of the next annual meeting of stockholders of the Issuer"

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VANLENT ANNE

(Last) (First) (Middle)

C/O TREVI THERAPEUTICS, INC.

195 CHURCH STREET, 16TH FLOOR

(Street)

NEW HAVEN CONNECTICUT 06510

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Trevi Therapeutics, Inc. [ TRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nonstatutory Stock Option (right to buy)	$13.45	06/03/2026		A		35,000		(1)	06/02/2036	Common Stock	35,000	$0.00	35,000	D

Explanation of Responses:

1. This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.

	/s/ Christopher Galletta, attorney-in-fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Trevi Therapeutics (TRVI) director Anne Vanlent report on this Form 4?

Anne Vanlent reported receiving a grant of stock options for 35,000 shares of Trevi Therapeutics common stock as director compensation, with a set exercise price and future vesting conditions tied to continued service.

How many Trevi Therapeutics (TRVI) shares are covered by the new stock options?

The new nonstatutory stock option grant covers 35,000 shares of Trevi Therapeutics common stock. These options give the director the right to buy shares at a fixed exercise price if and when they vest.

What is the exercise price of Anne Vanlent’s Trevi Therapeutics (TRVI) options?

The granted options have an exercise price of $13.45 per share. This means she can purchase Trevi Therapeutics common stock at $13.45 once the options vest and before they expire in 2036.

When do the new Trevi Therapeutics (TRVI) stock options vest for the director?

The options are scheduled to fully vest on the earlier of one year after the June 3, 2026 grant date or the next annual stockholder meeting, provided Anne Vanlent continues serving as a director, employee or consultant.

When do Anne Vanlent’s Trevi Therapeutics (TRVI) stock options expire?

The granted options expire on June 2, 2036. She must exercise any vested options before this expiration date or they will lapse, consistent with typical long-term equity compensation structures.